Alfredo Quijano Rubio

Alfredo Quijano Rubio has a diverse and extensive work experience in the field of scientific research and biotechnology.

Their most recent position was as the Co-Founder and Chief Scientific Officer (CSO) at Monod Bio, a role which they began in November 2021.

Prior to that, they worked at Neoleukin Therapeutics, where they held multiple roles. Alfredo began at Neoleukin Therapeutics in July 2018 as a Co-Founder and later took on the position of Senior Scientist starting in September 2020. Alfredo remained with the company until November 2021.

Before joining Neoleukin Therapeutics, Alfredo was a Graduate Student at the Institute for Protein Design at the University of Washington. Alfredo held this role from September 2016 to March 2021.

Prior to their time at the University of Washington, Alfredo worked as a Researcher at the Instituto de Biología Molecular y Celular de Plantas (IBMCP) from September 2015 to July 2016.

Alfredo Quijano Rubio's work experience highlights their expertise and involvement in cutting-edge scientific research and biotech startups.

Alfredo Quijano Rubio completed their education with a Doctor of Philosophy - PhD degree in Bioengineering and Biomedical Engineering from the University of Washington. Alfredo pursued this degree from 2016 to 2021. Prior to that, they obtained a Bachelor of Science - BS degree in Biotechnology from the Universitat Politècnica de València (UPV) where they studied from 2011 to 2015.